COVID-19: A cautious attitude toward “ivermectin”: Central Epidemic Headquarters
Korean epidemic authorities:
Negative opinion that “Ivermectin, a therapeutic agent for parasitic infections, is effective” for the treatment of new coronaviruses.
We are cautious, saying, “The safety and effects of overseas research have not been fully confirmed.”
Central Epidemic Countermeasures Headquarters; Director Chung Eun-kyung
On April 6th, a research team from Monash University in Melbourne, Australia
“Ivermectin” announced the experimental result that it suppresses the growth of new coronavirus within 48 hours.
But,
A research stage recommendation for a drug,
It has not been clinically validated.
Safety and effectiveness have not been confirmed yet.
Korea: Food and Drug Safety Agency
Antiparasitic drugs generally have low absorption.
Additional research such as clinical trials is required to develop it as a therapeutic agent.
Currently, antiparasitic drugs containing “ivermectin” are not permitted in Korea.
This means that one item is licensed for export.
“Ivermectin”:
It is a remedy for parasitic infections.
It was jointly developed by the American pharmaceutical company Merck in the 1970s and the Kitasato Institute in Japan.
KBS WORLD Radio
http://world.kbs.co.kr/service/news_view.htm?lang=j&Seq_Code=75414